Recent Updates — CLYM
Climb Bio announced initial Phase 2 PrisMN trial data for budoprutug, an anti-CD19 monoclonal antibody, in patients with primary membranous nephropathy (pMN). At Week 12, the 200 mg cohort demonstrated a mean PLA2R antibody reduction of 70%, with 38% of patients achieving immunologic remission. The 600 mg cohort showed deeper B-cell depletion compared to the lower dose. A separate case study in minimal change disease reported three-year steroid-free remission following treatment. Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases.
Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116/MIL116, an anti-APRIL monoclonal antibody in development for IgA nephropathy. The results from healthy volunteer trials demonstrated a ~70% reduction in galactose-deficient IgA1 (Gd-IgA1) and approximately 60% suppression of IgA at 12 weeks following an 800 mg dose. The data also showed greater than 90% free APRIL suppression sustained through the dosing interval, supporting a potential every-12-week regimen with a ~33-day half-life. CLYM116 was generally well tolerated with no serious adverse events. Climb Bio is currently enrolling patients in its NAVIGATE-2 Phase 2 trial and expects to initiate a global Phase 3 trial in 2027, pending regulatory feedback. The company operates as a clinical-stage biotechnology firm developing therapies for immune-mediated diseases.
On September 3, 2026, Climb Bio announced positive initial data from its Phase 1 trial of CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy. The study enrolled 46 healthy volunteers and demonstrated a ~29-day half-life, >90% free APRIL suppression, and 60-75% suppression of IgA and Gd-IgA1 following a single 320 mg dose. CLYM116 was generally well-tolerated with no serious adverse events or hypogammaglobulinemia. The company plans to initiate a Phase 3 registrational study in 2027, pending initial data from the ongoing NAVIGATE-2 Phase 2 trial expected in H1 2027. Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases.
Climb Bio reported second quarter 2026 financial results on August 6, 2026, showing a net loss of $13.5 million compared to $8.7 million in the prior year period. Cash and marketable securities totaled $239.2 million as of June 30, 2026, following an April private placement that generated approximately $110 million in gross proceeds, extending the cash runway into the second half of 2028. The company provided clinical updates for its lead programs: CLYM116 Phase 1 data will be presented at an R&D Spotlight on September 3, 2026, with dosing anticipated to begin in a Phase 2 IgA nephropathy trial in Q3 2026. Budoprutug trials continue across primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with data expected in Q4 2026. Climb Bio operates as a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases.
On June 29, 2026, Andrew Levin resigned from the Board of Directors and Breanna O'Reilly, Ph.D., was elected as a new director. Dr. O'Reilly's term expires in 2027 and she will receive an annual cash retainer of $40,000 and a stock option grant of 70,284 shares at an exercise price of $13.36 per share. Climb Bio, Inc. is a biotechnology company focused on developing therapeutic solutions.